Compounds > 4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine
Page last updated: 2024-09-03

4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine and rilpivirine

4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine has been researched along with rilpivirine in 1 studies

Compound Research Comparison

Studies
(4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine)		Trials
(4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine)		Recent Studies (post-2010)
(4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine)		Studies
(rilpivirine)		Trials
(rilpivirine)		Recent Studies (post-2010) (rilpivirine)
60058093513

Protein Interaction Comparison

ProteinTaxonomy4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine (IC50)rilpivirine (IC50)
Gag-Pol polyproteinHIV-1 M:B_HXB2R0.068
Cytochrome P450 1A2Homo sapiens (human)6.1612
Cytochrome P450 3A4Homo sapiens (human)1.7406
Cytochrome P450 2D6Homo sapiens (human)2.3635
Cytochrome P450 2C9 Homo sapiens (human)0.2818
Cytochrome P450 2C19Homo sapiens (human)0.3363
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.5
Reverse transcriptase/RNaseH Human immunodeficiency virus 10.0759
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.5

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E1

Other Studies

1 other study(ies) available for 4-amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3-d)pyrimidine and rilpivirine

ArticleYear
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
    Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2

    Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship

2009